Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 June;51(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 June;51(2):99-110

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

REWIEWS  MOLECULAR IMAGING IN PHARMACOLOGYFREEfree


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 June;51(2):99-110

Copyright © 2007 EDIZIONI MINERVA MEDICA

lingua: Inglese

Nuclear medicine applications in molecular imaging: 2007 update

Blankenberg F. G. 1, Strauss H. W. 2

1 Division of Pediatric Radiology F.G.B.-Department of Radiology Lucile Salter Packard Children’s Hospital, Stanford, CA, USA 2 Section of Nuclear Medicine H.W.S.-Department of Radiology Memorial Sloan Kettering Cancer Center, NY, USA


FULL TEXT  


This review examines several classes of radiolabeled agents, including analogs localizing in somatostatin, benzodiazepine and dopamine receptors; analogs of progesterone and estrogen; and agents localizing in lesions with hypoxia. It concludes the status of agents advocated for detecting angiogenesis and inflammation. The current clinical status of these agents, and their potential roles in diagnosis and treatment are discussed.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail